Literature DB >> 1939583

Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.

B Forghani1, J W Hurst, C S Chan.   

Abstract

A HeLa T4+ cell line persistently infected with human immunodeficiency virus type 1 (HIV-1) was used in an indirect immunofluorescent antibody assay (IFA) system to explore its potential suitability as an alternative source of viral antigen for confirmatory IFA in HIV serology. In a study of 121 serum samples chosen because they were reactive on repeat examination by enzyme immunoassay but nonspecific by IFA by using HIV-1-infected H9 cells (H9 IFA) or gave discrepant results by enzyme immunoassay and H9 IFA, the specificity and sensitivity of the HeLa T4+ IFA were comparable to those of Western blot (immunoblot), and identification of the true positive samples among these discrepant or nonspecific samples by HeLa T4+ IFA was approximately twice that by H9 IFA. The primary advantages of using the HeLa cell line rather than lymphoid cell lines in IFA are that cells can be grown as a monolayer and that the individual cells are much larger. The cell membrane, cytoplasm, and nucleus are easily discernible; this allows specific and nonspecific staining to be distinguished. At least eight different nonspecific nuclear and cytoplasmic staining patterns were identified in this study by using T4+ cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939583      PMCID: PMC270311          DOI: 10.1128/jcm.29.10.2266-2272.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  47 in total

1.  Comparison of biotinylated DNA and RNA probes for rapid detection of varicella-zoster virus genome by in situ hybridization.

Authors:  B Forghani; G J Yu; J W Hurst
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Screening for HIV: can we afford the false positive rate?

Authors:  K B Meyer; S G Pauker
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

3.  Comparison of enzyme immunoassays and an immunofluorescence test for detection of antibody to human immunodeficiency virus in African sera.

Authors:  G Vercauteren; G van der Groen; P Piot
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

4.  Seroimmunology of AIDS retrovirus infection. I. Use of immunofluorescence assay to confirm sera with ELISA reactivity.

Authors:  A A Imrie; S Kehrer; G W Smith; R Penny; D A Cooper
Journal:  Pathology       Date:  1986-10       Impact factor: 5.306

5.  An improved immunoblotting procedure for the detection of antibodies against HIV.

Authors:  R Thorpe; M D Brasher; C R Bird; A J Garrett; J P Jacobs; P D Minor; G C Schild
Journal:  J Virol Methods       Date:  1987-05       Impact factor: 2.014

6.  Evaluation of the indirect immunofluorescence assay as a confirmatory test for detecting antibodies to the human immunodeficiency virus.

Authors:  T M McHugh; D P Stites; C H Casavant; J R Carlson; J Yee; P A McVay; M P Busch; J A Levy
Journal:  Diagn Immunol       Date:  1986

7.  Comparison of indirect immunofluorescence and Western blot for detection of anti-human immunodeficiency virus antibodies.

Authors:  J R Carlson; J Yee; S H Hinrichs; M L Bryant; M B Gardner; N C Pedersen
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

8.  Antibody response to human immunodeficiency virus after primary infection.

Authors:  D A Cooper; A A Imrie; R Penny
Journal:  J Infect Dis       Date:  1987-06       Impact factor: 5.226

9.  Diagnosis of human immunodeficiency virus infection by immunoassay using a molecularly cloned and expressed virus envelope polypeptide. Comparison to Western blot on 2707 consecutive serum samples.

Authors:  D S Burke; B L Brandt; R R Redfield; T H Lee; R M Thorn; G A Beltz; C H Hung
Journal:  Ann Intern Med       Date:  1987-05       Impact factor: 25.391

10.  Indirect immunofluorescence assay for antibodies to human immunodeficiency virus.

Authors:  E T Lennette; S Karpatkin; J A Levy
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.